Combination therapies for treatment of breast cancer

TW202633648APending Publication Date: 2026-08-16GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115117639
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-24
Filing Date
2020-12-01
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001073617_001
    Figure TWG2TA001073617_001
  • Figure TWG2TA001073617_002
    Figure TWG2TA001073617_002
  • Figure TWG2TA001073617_003
    Figure TWG2TA001073617_003
Patent Text Reader

Abstract

Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+ / HER2-) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
Need to check novelty before this filing date? Find Prior Art